Content by Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of the SEQuoia Express Stranded RNA Library Prep Kit.

The importance of standardization for research and diagnostic result reproducibility

Explore how flow cytometry innovations expand and accelerate cell profiling.

Putting the pieces together for molecular diagnostics and infectious disease research

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today introduced a range of antibodies that are specific to cemiplimab (Libtayo) and inhibit the binding of the drug to its target, human programmed death receptor-1 (PD-1).

Researchers use ddPCR to monitor quality at each stage of therapy development.

Researchers turn to ddPCR for accurate nucleic acid quantification during biotherapeutic development.

Learn about wastewater-based epidemiology—from its conception to its present state and into its future.

Increasing automation, speed, and multiplexed analysis at all stages of drug discovery

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of a range of anti-daratumumab antibodies that are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38. These highly specific and high-affinity recombinant antibodies are suitable for bioanalysis and drug monitoring of daratumumab and its biosimilars.

Immunoassays for detecting, tracking, and testing SARS-CoV-2 antibody responses

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today introduced four inhibitory antibodies that are highly specific to pertuzumab (Perjeta).

Embark on the journey of cell and gene therapy—from its conception and development, to its present state, and into its future.